This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Thank you for your reply. I only have this to say in response. You said “I think you would agree that the treatment you receive in 10 years will be better than the one you would receive today”. To that I say: while I believe that is likely to be the case, I would not go so far as to bet my life on it…which, in a nutshell, is the point I was making earlier. In other words, in the face of evidence of possible progression, I would not delay treatment in favor of holding out for a better one down the road. I hope we are both in agreement on that.
Below is a snippet from the Australian Cancer Council.
Active surveillance entails close follow-up of patients diagnosed with low-risk prostate cancer. The objective is to avoid unnecessary treatment of men with indolent cancer and treat only those who show signs of disease progression, to avoid treatment-related effects that may reduce quality of life. Definitive therapy is offered at a time when disease progression is detected and cure is deemed possible.
The optimal protocol for active surveillance is uncertain. Monitoring usually involves prostate specific antigen (PSA) testing, digital rectal examination (DRE), prostate biopsies, and, in specialised centres, consideration of multi-parametric prostate magnetic resonance imaging (MRI). Evidence is lacking about the optimal frequency of monitoring and the most appropriate triggers for intervention. Whilst many active surveillance protocols have been reported in the literature, these vary in their inclusion criteria and monitoring procedures. To date, these active surveillance protocols have not been validated in randomised controlled trials. More importantly, they have not been examined with respect to overall and/or prostate cancer-specific mortality.
John,
This is a copy of Roger's post above that is very relevant to this thread:
Another report on Active Surveillance
I found this report interesting:
Prostate Cancer Surveillance Appears Safe Through 15 Years
Frontline Medical News, 2014 Dec 15, MA Moon NEWS
Dr. Laurence Klotz
Active surveillance appears to be safe through 15 years of follow-up for men who have low-risk prostate cancer, according to a report published online Dec. 15 in the Journal of Clinical Oncology.
In extended follow-up of a prospective cohort study begun in 1995, 993 men (current median age, 68 years; range, 41-89 years) with low-risk prostate cancer were assessed. Active surveillance consisted of PSA testing every 3 months for the first 2 years after diagnosis and then every 6 months thereafter, with repeat biopsy at 1 year and then every 3-4 years until the age of 80. These study participants were offered radical intervention only if the disease showed signs of progression, said Dr. Laurence Klotz of Sunnybrook Health Sciences Centre, University of Toronto, and his associates.
A total of 149 patients died, 819 were alive, and 25 were lost to follow-up. Only 15 men (1.5%) died from prostate cancer, and an additional 13 men with confirmed metastases either are alive (9 patients) or died from other causes (4 patients). Overall, the risk of dying from another cause was nearly 10 times greater than that for dying from prostate cancer (HR, 9.2). Even among men younger than 70, who had lower competing risks of death from other causes than older men, the risk of death from another cause was almost six times greater than that for death from prostate cancer (HR, 5.8), the investigators said (J. Clin. Oncol. 2014 Dec. 15 [doi:10.1200/JCO.2014.55.1192]).
The rate of patients who developed PSA failure during follow-up was 2.8% at 5 years and 10.2% at 10 years after diagnosis. These outcomes are consistent with those in low-risk patients managed with initial definitive intervention such as radiotherapy and surgery, Dr. Klotz and his associates added.
This study was supported by the Prostate Cancer Research Foundation of Canada. Dr. Klotz and his associates reported having no financial conflicts of interest.
